Opinion|Videos|May 2, 2025
Final Thoughts on Type 1 Diabetes: Innovations, Challenges and the Road Ahead
A panelist discusses how the adoption of C-peptide preservation as a critical end point in clinical trials represents a paradigm shift in type 1 diabetes (T1D) research, moving beyond glucose control alone to focus on disease-modifying therapies that can maintain endogenous insulin production and potentially alter the fundamental course of the disease.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Many emerging therapies are using C-peptide levels as an end point for assessing efficacy. How does this shift impact treatment strategies and clinical research in T1D?
- If there is one key message you would like health care decision-makers to take away from this discussion regarding T1D, what would it be?
- To close our interview, what are some promising avenues for future research and innovation in the field of T1D? What are you most excited about in the future?
Advertisement
Related to this article
The rule requires pharmacy benefit managers to disclose rebates and discounts, money made from spread pricing and incentives for formulary placement.
As pulmonary fibrosis treatment options grow, Rachael Prusi of Prime Therapeutics says health plans should lean on guidelines and strong case management.
Patients with pulmonary fibrosis wait about two years for a diagnosis. Rachael Prusi of Prime Therapeutics explains how health plans can find them sooner.
The FDA has approved three HIV products since June 2025, and the late-stage pipeline is testing how far apart doses can be spaced. Here are the milestones payers and health systems should track through 2027.
Hiva Pourarsalan at AMCP Nexus explains how MFP shifts Medicare drug pricing, disrupting rebates and contracting and forcing payers to rethink formularies.
EHRs miss many cancer deaths. Linking electronic health records with claims and third‑party death data sharply improves accuracy, Tempus reports at AMCP Nexus.
CMS projects roughly 2.3 million people will lose Medicaid coverage in 2027 under the new community engagement requirements, also referred to as work requirements: four in ten to paperwork, not noncompliance. Arkansas showed how that happens; here is what plans can learn before the clock starts.
Managed care leaders should vet AI tools before use and recheck them over time, and pharmacists need AI literacy, according to two AMCP Nexus 2026 presenters.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
5 things you should know about the midterms and healthcare
2
2.3 million reasons to rethink member communications before Jan. 1
3
5 things you should know about intismeran, the Moderna-Merck cancer vaccine
4
Prime's Pat Gleason flags cost, timing gaps in type 1 diabetes screening | AMCP Nexus 2026
5